EpiCept Corporation To Present at The Canaccord Adams Global Growth Conference
TARRYTOWN, N.Y., Aug. 1 / -- EpiCept Corporation (Nasdaq and OMX Nordic
Exchange: EPCT) today announced that Jack Talley, President and CEO, will be
presenting at the Canaccord Adams Global Growth Conference on August 7, 2007 at
8:00 a.m. EDT at the InterContinental Boston. Mr. Talley will present a company
overview.
(Logo: http://www.newscom.com/cgi-bin/prnh/20020513/NYM112LOGO )
Mr. Talley will join executives from nearly 270 public and private companies for
the conference, one of the longest-running institutional events focused
exclusively on growth companies.
The presentation will be available live via webcast on August 7, 2007 and for 90
days thereafter and can be accessed by visiting http://www.epicept.com.
The Canaccord Adams Global Growth Conference is one of the oldest and largest
programs showcasing both publicly traded and privately held growth companies.
Many of the presenting public companies are covered by Canaccord Adams' global
team of equity analysts. To learn more about the conference, please contact
Nadine Miller at 617.371.3842 or Nadine.Miller@CanaccordAdams.com.
About EpiCept Corporation
EpiCept is focused on unmet needs in the treatment of pain and cancer. EpiCept
has a staged portfolio of pharmaceutical product candidates with several pain
therapies in late-stage clinical trials, and a lead oncology compound (for acute
myeloid leukemia, or AML) with demonstrated efficacy in a Phase III trial; a
marketing authorization application for this compound has been submitted in
Europe. EpiCept is based in Tarrytown, N.Y., and its research and development
team in San Diego is pursuing a drug discovery program focused on novel
approaches to apoptosis.
Forward-Looking Statements
This news release and any oral statements made with respect to the information
contained in this news release, contains forward-looking statements within the
meaning of the Private Securities Litigation Reform Act of 1995. Such
forward-looking statements include statements which express plans, anticipation,
intent, contingency, goals, targets, future development and are otherwise not
statements of historical fact. These statements are based on EpiCept's current
expectations and are subject to risks and uncertainties that could cause actual
results or developments to be materially different from historical results or
from any future results expressed or implied by such forward-looking statements.
Factors that may cause actual results or developments to differ materially
include: the risk that Myriad's development of Azixa will not be successful, the
risk that Azixa will not receive regulatory approval or achieve significant
commercial success, the risk that we will not receive any significant payments
under our agreement with Myriad, the risk that the development of our other
apoptosis product candidates will not be successful, the risk that our ASAP
technology will not yield any successful product candidates, the risk that
clinical trials for NP-1 will not be successful, that NP-1 will not receive
regulatory approval or achieve significant commercial success, the risk that
Ceplene will not receive regulatory approval or marketing authorization in the
EU, the risk that our other product candidates that appeared promising in early
research and clinical trials do not demonstrate safety and/or efficacy in
larger-scale or later stage clinical trials, the risk that EpiCept will not
obtain approval to market any of its product candidates, the risks associated
with reliance on additional outside financing to meet its capital requirements,
the risks associated with dependence upon key personnel, the risks associated
with reliance on collaborative partners and others for further clinical trials,
development, manufacturing and commercialization of our product candidates; the
cost, delays and uncertainties associated with our scientific research, product
development, clinical trials and regulatory approval process; our history of
operating losses since our inception; competition; litigation; risks associated
with our ability to have our common stock readmitted to trading on The Nasdaq
Global Market; risks associated with prior material weaknesses in our internal
controls; and risks associated with our ability to protect our intellectual
property. These factors and other material risks are more fully discussed in
EpiCept's periodic reports, including its reports on Forms 8-K, 10-Q and 10-K
and other filings with the U.S. Securities and Exchange Commission. You are
urged to carefully review and consider the disclosures found in EpiCept's
filings which are available at www.sec.gov or at www.epicept.com. You are
cautioned not to place undue reliance on any forward-looking statements, any of
which could turn out to be wrong due to inaccurate assumptions, unknown risks or
uncertainties or other risk factors.
EPCT-GEN
SOURCE EpiCept Corporation
-0- 08/01/2007
/CONTACT: Robert W. Cook of EpiCept Corporation, +1-914-606-3500,
rcook@epicept.com; or Investors, Kim Sutton Golodetz, +1-212-838-3777,
kgolodetz@lhai.com, or Bruce Voss, +1-310-691-7100, bvoss@lhai.com, both of
Lippert-Heilshorn & Associates; or Media, Greg Kelley of Feinstein Kean
Healthcare, +1-617-577-8110, gregory.kelley@fkhealth.com, all for EpiCept
Corporation/
/Photo: NewsCom: http://www.newscom.com/cgi-bin/prnh/20020513/NYM112LOGO
AP Archive: http://photoarchive.ap.org
PRN Photo Desk, photodesk@prnewswire.com/
/Web site: http://www.epicept.com /
(EPCT)
EpiCept Corporation To Present at The Canaccord Adams Global Growth Conference
| Source: Immune Pharmaceuticals Inc